TigaTx Overview
- Year Founded
-
2018
- Status
-
Acquired/Merged
- Employees
-
7
- Latest Deal Type
-
M&A
TigaTx General Information
Description
Developer of a proprietary platform technology designed to activate the body's neutrophils to fight cancer. The company's technology utilizes a seasoned group of drug developers to develop uniquely engineered IgA monoclonal antibodies that increase the capacity of the neutrophils in the body to fight cancer cells, enabling cancer patients to improve their health.
Contact Information
Website
www.tigatx.com(Operating Subsidiary)
Corporate Office
- 75 Kneeland Street
- 14th Floor
- Boston, MA 02111
- United States
Corporate Office
- 75 Kneeland Street
- 14th Floor
- Boston, MA 02111
- United States
TigaTx Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Merger/Acquisition | 19-Mar-2025 | Completed | Generating Revenue | |||
| 4. Grant | 18-Dec-2024 | Completed | Generating Revenue | |||
| 3. Later Stage VC | 26-Jul-2024 | Completed | Generating Revenue | |||
| 2. Early Stage VC | 01-Jan-2020 | Completed | Generating Revenue | |||
| 1. Early Stage VC | 21-Sep-2018 | Completed | Generating Revenue |
TigaTx Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
TigaTx Patents
TigaTx Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4274605-A1 | Indinavir based chemical dimerization t cell engager compositions | Pending | 11-Jan-2021 | ||
| US-20240190987-A1 | Engineered epcam binding antibodies | Pending | 11-Jan-2021 | ||
| EP-4274605-A4 | Indinavir based chemical dimerization t cell engager compositions | Pending | 11-Jan-2021 | ||
| AU-2020248645-A1 | Engineered iga antibodies and methods of use | Pending | 27-Mar-2019 | ||
| EP-3947441-A1 | Engineered iga antibodies and methods of use | Pending | 27-Mar-2019 | C07K16/00 |
TigaTx Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
TigaTx Former Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| ARPA-H | Government | |||
| Alexandria Venture Investments | Venture Capital | Minority | ||
| BioGeneration Ventures | Venture Capital | Minority | ||
| Boehringer Ingelheim Venture Fund | Corporate Venture Capital | Minority | ||
| Civilization Ventures | Venture Capital | Minority |
TigaTx FAQs
-
When was TigaTx founded?
TigaTx was founded in 2018.
-
Where is TigaTx headquartered?
TigaTx is headquartered in Boston, MA.
-
What is the size of TigaTx?
TigaTx has 7 total employees.
-
What industry is TigaTx in?
TigaTx’s primary industry is Drug Discovery.
-
Is TigaTx a private or public company?
TigaTx is a Private company.
-
What is TigaTx’s current revenue?
The current revenue for TigaTx is .
-
Who are TigaTx’s investors?
ARPA-H, Alexandria Venture Investments, BioGeneration Ventures, Boehringer Ingelheim Venture Fund, and Civilization Ventures are 5 of 13 investors who have invested in TigaTx.
-
When was TigaTx acquired?
TigaTx was acquired on 19-Mar-2025.
-
Who acquired TigaTx?
TigaTx was acquired by Epsilogen.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
